News
Nimacimab is a first-in-class peripherally-restricted negative allosteric modulator antibody inhibitor of CB1 signaling Phase 1 results for SBI-100 Ophthalmic Emulsion, a first-in-class CB1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback